LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Charlier, Filip"
  2. AU="Mihalopoulos, N"
  3. AU="Fernandez, S Gomez"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Unifocal Right-Sided Ablation Treatment for Neurally Mediated Syncope and Functional Sinus Node Dysfunction Under Computed Tomographic Guidance.

    Debruyne, Philippe / Rossenbacker, Tom / Collienne, Christine / Roosen, John / Ector, Bavo / Janssens, Luc / Charlier, Filip / Vankelecom, Bart / Dewilde, Willem / Wijns, William

    Circulation. Arrhythmia and electrophysiology

    2018  Band 11, Heft 9, Seite(n) e006604

    Abstract: Background Biatrial, extensive, and complex ablation strategies have been published for the treatment of neurally mediated syncope, sinus node dysfunction, and functional atrioventricular block. We have developed a less extensive and more specific ... ...

    Abstract Background Biatrial, extensive, and complex ablation strategies have been published for the treatment of neurally mediated syncope, sinus node dysfunction, and functional atrioventricular block. We have developed a less extensive and more specific approach compared with previously published cardioneuroablation strategies, called cardio-neuromodulation. It is based on tailored vagolysis of the sinoatrial node through partial ablation of the anterior right-ganglionated plexus, preferentially through a right-sided approach. Methods Patients with syncope were enrolled between December 2016 and December 2017. They were assigned to group A if they had a positive head-up tilt test and to group B if they presented with a pause ≥3 seconds. The area to target during cardio-neuromodulation was designed offline on a computed tomographic scan. Slow heart rates and pauses were compared during 24-hour rhythm registration at baseline, at 1-month follow-up, and 6-month follow-up. Syncope burden was assessed before the procedure and at 3- and 6-month follow-up. Results Twenty patients underwent cardio-neuromodulation through a right-sided approach (12 in group A, 8 in group B). The first application of radiofrequency energy led to a P-P interval shortening >120 ms in all 20 patients. After a mean±SD ablation time of 7±4 minutes and mean ablated surface area of 11±6 mm
    Mesh-Begriff(e) Action Potentials ; Adult ; Aged ; Belgium ; Bradycardia/etiology ; Bradycardia/physiopathology ; Catheter Ablation/adverse effects ; Catheter Ablation/methods ; Electrocardiography, Ambulatory ; Female ; Heart Rate ; Humans ; Male ; Middle Aged ; Prospective Studies ; Radiography, Interventional/methods ; Recurrence ; Sick Sinus Syndrome/complications ; Sick Sinus Syndrome/diagnosis ; Sick Sinus Syndrome/physiopathology ; Sick Sinus Syndrome/surgery ; Syncope, Vasovagal/diagnosis ; Syncope, Vasovagal/etiology ; Syncope, Vasovagal/physiopathology ; Tilt-Table Test ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome ; Young Adult
    Sprache Englisch
    Erscheinungsdatum 2018-10-25
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2426129-4
    ISSN 1941-3084 ; 1941-3149
    ISSN (online) 1941-3084
    ISSN 1941-3149
    DOI 10.1161/CIRCEP.118.006604
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Formation of thermal coagulum on multielectrode catheters during phased radiofrequency energy ablation of persistent atrial fibrillation.

    Debruyne, Philippe / Rossenbacker, Tom / Vankelecom, Bart / Charlier, Filip / Roosen, John / Ector, Bavo / Janssens, Luc

    Pacing and clinical electrophysiology : PACE

    2014  Band 37, Heft 2, Seite(n) 188–196

    Abstract: Background: Radiofrequency ablation (RFA) can unfavorably cause coagulum on the ablation electrode. The aim of this study was to assess this phenomenon on three different multielectrode catheters used to treat persistent atrial fibrillation with duty- ... ...

    Abstract Background: Radiofrequency ablation (RFA) can unfavorably cause coagulum on the ablation electrode. The aim of this study was to assess this phenomenon on three different multielectrode catheters used to treat persistent atrial fibrillation with duty-cycled RFA.
    Methods and results: Twenty-six consecutive patients have been treated with the pulmonary vein ablation catheter (PVAC) and the multiarray ablation catheter (MAAC). In 13 patients, additional ablation with the multiarray septal catheter (MASC) has been performed. The multichannel RF generator GENius™ (Medtronic Inc., Minneapolis, MN, USA) independently delivered energy in a bipolar and unipolar mode (ratio of 4/1, 2/1, or 1/1) to any of the electrodes. Versions 14.2, 14.3, and 14.4 of the generator were used. Coagulum presence was determined postablation by careful visual inspection of the catheter electrodes. No coagulum formation was visualized on the PVACs. Coagulum formation was visualized in 59% of the electrodes of the MAACs using a 2/1 mode and the 14.2 software version versus 69% using the 14.4 version and a 2/1 mode (P = 0.7) versus 14% of the electrodes applying a 1/1 ratio and the 14.4 software version (P < 0.001).
    Conclusions: Duty-cycled RFA in 2/1 bipolar/unipolar ratio generates a substantial frequency of coagulum formation on the multielectrode catheters MAAC and MASC. The use of the 14.4 version of the software to drive the RF generator and the use of energy in the default 1/1 bipolar/unipolar ratio could significantly reduce the frequency of coagulum formation, but so far, could not completely overcome it. The PVAC did not form coagulum, regardless of generator version or energy ratio used.
    Mesh-Begriff(e) Adult ; Atrial Fibrillation/blood ; Atrial Fibrillation/surgery ; Blood Coagulation/radiation effects ; Catheter Ablation/adverse effects ; Catheter Ablation/instrumentation ; Chronic Disease ; Electrodes/adverse effects ; Embolism/etiology ; Equipment Design ; Equipment Failure ; Equipment Failure Analysis ; Female ; Hot Temperature/adverse effects ; Humans ; Male ; Middle Aged ; Radio Waves ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2014-02
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 424437-0
    ISSN 1540-8159 ; 0147-8389
    ISSN (online) 1540-8159
    ISSN 0147-8389
    DOI 10.1111/pace.12256
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial.

    Mertens, Paul / Maes, Alex / Nuyts, Johan / Belmans, Ann / Desmet, Walter / Esplugas, Enric / Charlier, Filip / Figueras, Jaime / Sambuceti, Gianmario / Schwaiger, Markus / Mortelmans, Luc / Van de Werf, Frans

    American heart journal

    2006  Band 152, Heft 1, Seite(n) 125.e1–8

    Abstract: Background: Inflammatory responses induced by reperfusion of previously ischemic myocardial tissue may lead to further damage of the microvascular structures. A group of cell adhesion molecules, named selectins, initiate those inflammatory changes at ... ...

    Abstract Background: Inflammatory responses induced by reperfusion of previously ischemic myocardial tissue may lead to further damage of the microvascular structures. A group of cell adhesion molecules, named selectins, initiate those inflammatory changes at the endothelial wall surface. Recombinant P-selectin glycoprotein ligand-immunoglobulin (rPSGL-Ig), a P-selectin antagonist, was shown to have beneficial effects in several animal models of acute myocardial ischemia. We performed a mechanistic study with positron emission tomography to test the potential benefits of rPSGL-Ig in patients with ST-segment elevation acute myocardial infarction.
    Methods: Patients with ST-elevation acute myocardial infarction presenting within the first 6 hours of onset of chest pain were enrolled. All patients received alteplase. Patients were randomly assigned in a 1:1:1 ratio to 3 treatment groups: placebo; 75 mg rPSGL-Ig; 150 mg rPSGL-Ig, given intravenously. Coronary angiography was performed 90 minutes after the start of thrombolytic therapy for TIMI flow grading. Myocardial blood flow (MBF) was measured with 13NH3 at rest and after adenosine administration on day 5. Myocardial blood flow at rest was measured again at day 30, followed by measurement of 18FDG uptake. In addition, a multigated acquisition, gated equilibrium blood pool study was performed at day 30. Continuous 12-lead electrocardiogram recording was performed during the first 24 hours.
    Results: The trial was prematurely stopped by the sponsor for lack of efficacy in an accompanying larger trial after enrolling 88 patients in the current study. Median MBF in the infarct-related territory (expressed as percentage of the normalized blood flow) at day 5 was similar in the 3 treatment groups (9.1% in the placebo group vs 3.8% in the 75-mg dose and 4.3% in the 150-mg rPSGL-Ig treatment group; P = not significant). No significant differences in MBF reserve, myocardial metabolism, ST-segment resolution, left ventricular ejection fraction, or TIMI flow grade were found among the 3 groups.
    Conclusions: In this prematurely stopped mechanistic study, there was no evidence of a benefit of rPSGL-Ig given as an adjunct to thrombolysis on epicardial vessel patency, myocardial tissue reperfusion, or recovery of function.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Coronary Angiography ; Coronary Vessels/physiology ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents/therapeutic use ; Humans ; Male ; Membrane Glycoproteins/administration & dosage ; Membrane Glycoproteins/therapeutic use ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Myocardial Infarction/drug therapy ; Myocardial Infarction/physiopathology ; Positron-Emission Tomography ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use ; Regional Blood Flow ; Stroke Volume ; Thrombolytic Therapy ; Tissue Plasminogen Activator/therapeutic use ; Tomography, Emission-Computed, Single-Photon
    Chemische Substanzen Fibrinolytic Agents ; Membrane Glycoproteins ; P-selectin ligand protein ; Recombinant Proteins ; Tissue Plasminogen Activator (EC 3.4.21.68)
    Sprache Englisch
    Erscheinungsdatum 2006-07
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2006.04.020
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang